The Claim
Elevating ANGPTL7 protein levels in mouse eyes via intravitreal or intracameral injection increases intraocular pressure by 2–5 mmHg over 7 days, and ANGPTL7 is sufficient to raise eye pressure and may contribute to pathological elevation in glaucoma.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Increasing ANGPTL7 protein in mouse eyes causes intraocular pressure to rise by 2–5 mmHg within 7 days, and this protein is sufficient to elevate eye pressure in a model of glaucoma.
See the scientific wording
Elevating ANGPTL7 protein levels in mouse eyes via intravitreal or intracameral injection increases intraocular pressure by 2–5 mmHg over 7 days, indicating that ANGPTL7 is sufficient to raise eye pressure and may contribute to pathological elevation in glaucoma.
A protein called ANGPTL7 builds up in the drainage system of the eye, causing a sticky mesh of material to thicken around the drainage channels. This thickening blocks the fluid inside the eye from flowing out properly, so the fluid builds up and pushes harder against the eye walls, raising the pressure inside.
What the research says
1 studyStudy: ANGPTL7, a therapeutic target for increased intraocular pressure and glaucoma
When scientists added more ANGPTL7 protein to mice's eyes, the pressure inside their eyes went up — just like the claim says. When they removed the protein, the pressure went down. This proves ANGPTL7 directly affects eye pressure.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.